Cell and gene therapies are often delayed by technical and regulatory issues
News
Miranda Dini launches GOLD amid industry shifts
New consultancy aims to deliver personalised senior expertise in healthcare communications
Genfit reports promising phase 1b data in cholangiocarcinoma
Results show disease control and tumour shrinkage with GNS561 and MEK inhibitor combination
GRI Bio reports positive phase 2a data in idiopathic pulmonary fibrosis
Trial shows GRI-0621 improved lung function with signs of fibrosis resolution
Immunotherapy combination shows unprecedented results in multiple myeloma
MajesTEC-3 study supports teclistamab plus daratumumab SC as potential standard of care
Modus Therapeutics advances sevuparin study in chronic kidney disease with anemia
Proof-of-concept phase begins with first patient enrolled
Five-year study confirms durable efficacy of etranacogene dezaparvovec
Gene therapy shows sustained benefit for adults with haemophilia B
Enterprise Therapeutics publishes results of phase 1 study of ETD001
Novel inhaled ENaC blocker shows promise for treatment of cystic fibrosis
Rybrevant accepted in Scotland for lung cancer treatment
SMC approves targeted therapy for patients with EGFR exon 20 insertion mutations
Early use of CARVYKTI shows lasting remissions in multiple myeloma
Johnson & Johnson reports phase 3 data highlighting durable outcomes and immune fitness benefits
Bayer begins phase 2 trial of new Alport syndrome therapy
New study to test Sema3A antibody in rare genetic kidney disease
Johnson & Johnson wins EU approval for new gMG treatment
Nipocalimab authorised for adults with antibody-positive generalised myasthenia gravis
Pharvaris reports positive phase 3 results for HAE treatment
Deucrictibant shows rapid symptom relief and strong safety profile in RAPIDe-3 study
AlzeCure secures EU grant for Alzheimer’s drug trial
Funding supports phase 2 study of NeuroRestore ACD856 in patients
Vandria reports positive phase 1 data for Alzheimer’s drug candidate
Company highlights safety and target engagement results for VNA-318 at CTAD meeting
